Breast Cancer—Local/Regional/Adjuvant Abstract e12500: Adverse effects of adjuvant tamoxifen treatment on bone mineral density in premenopausal breast cancer patients: A systematic review and meta-analysis. First Author: Chihwan Cha, MD Abstract e12501: Impact of a randomized weight loss trial on breast tissue markers in breast cancer survivors. First Author: Christina Marie Dieli-Conwright, PhD, MPH Abstract e12502: Impact of the COVID-19 pandemic on health care activities at a Uruguayan mastology teaching unit: Preliminary results. First Author: Cecilia Castillo Abstract e12504: Integrative oncology therapy for adverse treatment effects in young women with breast cancer. First Author: Yancey Warren, MD, MAT Abstract e12505: The effect of non-oncology drugs on clinical and genomic risk in early luminal breast cancer. First Author: Barliz Waissengrin, MD Abstract e12506: Abemaciclib, a CDK4 and 6 inhibitor with unique pharmacological properties for breast cancer therapy. First Author: Raquel Torres-Guzmán Abstract e12507: A simulation model-based clinical decision tool to guide personalized treatment based on individual characteristics: Does 21-gene recurrence score assay testing change decisions? First Author: Jinani Jayasekera, PhD Abstract e12508: Five-day accelerated partial breast irradiation (APBI) using intensity modulated radiation therapy (IMRT) in stage 0-II breast cancer: A report of 214 cases with up to 39 month follow-up. First Author: Rufus J. Mark, MD Abstract e12510: Advanced breast cancer at presentation (ABC-p) in octogenarian women (OW): Specific elderly-devoted risk tests(SEDRT) (CARG+CRASH) as new tools to prevent serious/irreversible adverse reactions (AR) in frail patients. First Author: Ignazio Ugo Carreca, MD, MDCM, PhD Abstract e12511: Application of RSClin to guide treatment recommendations for premenopausal patients with early-stage hormone-positive breast cancer and intermediate risk oncotype recurrence scores. First Author: Brittney Shulman Zimmerman, MD Abstract e12512: OncotypeDx scores according to race/ethnicity and age in a diverse cohort of breast cancer patients. First Author: Eileen Chen, BS Abstract e12513: Weight changes according to treatment in a diverse cohort of breast cancer patients. First Author: Jami Aya Fukui, MD Abstract e12514: Breast cancer as seen at the Nairobi Hospital. First Author: Nicholas Anthony Othieno-Abinya, MBChB, M'Med, FRCP Abstract e12515: Retrospective analysis of HER2-low in young breast cancer patients. First Author: Abeid Mohamed Athman Omar, MD Abstract e12516: Thromboembolism (TE) and adjuvant endocrine therapy (AET) in hormone receptor positive (HR+) early breast cancer (EBC): Did the evolution of treatment change the incidence of the adverse event? A metanalysis. First Author: Luca Moscetti, MD Abstract e12517: Study on the extract of Huangqi and Ezhu for the crosstalk of exosomes mediating tamoxifen resistance on LCC9 cells. First Author: Shasha Cui Abstract e12518: Impact of oncotype Dx score on treatment and long-term outcomes. First Author: Surbhi Warrior, MD MPH Abstract e12519: Association between estrogen receptor status and Oncotype Dx breast recurrence score. First Author: Noman Ahmed Jang Khan Abstract e12520: Comparing practice patterns and outcomes for early-stage hormone receptor- positive and node-positive breast cancer patients with high-intermediate-risk Oncotype Dx scores in the National Cancer Database. First Author: Keerthi Tamragouri, MD Abstract e12521: Concordance between 21-gene score (Oncotype DX) and clinical-pathologic prognostic models in early-breast cancer in Medellín, Colombia. First Author: Mauricio Lujan Abstract e12522: Trends in use of ovarian suppression (OS) for premenopausal patients with early-stage hormone positive breast cancer and Intermediate Risk (IR) Oncotype Recurrence Scores (RS) from 2006-2020: A retrospective database analysis. First Author: Sara Malin Hovstadius, BS Abstract e12523: Projected long-term impact of adjuvant trastuzumab emtansine (T-DM1) on metastatic breast cancer occurrence in Turkey. First Author: David J. Press, MPhil, PhD Abstract e12524: Impact of RxPONDER on breast cancer treatment in an academic-community hospital. First Author: Be Saito Abstract e12525: Latent atherosclerosis as a risk factor in chemotherapy-induced cardiomyopathy. First Author: Yuliya Paulenka Abstract e12526: Integrated immune-related gene signature to predict clinical outcome for patients with luminal B breast cancer. First Author: Xiaying Kuang, MD, PhD Abstract e12528: Phase II double blinded randomized placebo-controlled trial of minocycline to ameliorate chemotherapy-induced cognitive changes in breast cancer (BC) patients. First Author: Jessica M. Sharpe, MD, PhD Abstract e12529: An analysis of lines of treatment and survival analysis in older Indigenous and Nonindigenous women of Western Australia with breast cancer. First Author: Azim Khan, MBBS, AMC Abstract e12531: Use of strain rate imaging for early detection of epirubicin-induced cardiotoxicity in patients with breast cancer. First Author: Vasiliki Michalaki, MD, PhD Abstract e12532: Tolerance of aromatase inhibitors in post-menopausal patients with early- stage hormone receptor positive (HR+) breast cancer: A real-world retrospective analysis in a large oncotype database. First Author: Shana Berwick, MD Abstract e12533: Clinical significance of crown-like structures to trastuzumab response in patients with primary invasive HER2+ breast cancer. First Author: Constantinos Savva, MD, MRCP, MSc, PhD (c) Abstract e12534: Metaplastic breast cancer: Disease characteristics and outcome in Arab women. First Author: Adher Alsayed Abstract e12535: Automated immunostaining-free prediction of breast carcinoma ER and PR status, Ki67 count, patient therapy stratification index and quantification of prognostic quiescence burden in TNBC from pretreatment H&E stained histopathology images in breast cancer. First Author: Tathagata Dasgupta, PhD Abstract e12536: Recurrence rate according to Oncotype Dx recurrence score (RS) in women with estrogen receptor (ER) positive, Her2 negative and 1 to 3 positive nodes: Real-world data in a Mexican private institution. First Author: Geovani Amador, MD Abstract e12537: Scalp cooling to reduce alopecia as a barrier to chemotherapy. First Author: Isabel M. Pupo Wiss Abstract e12538: Breast cancer after IVF: Can ovary stimulation and follicular response affect prognostic factors? First Author: Maxim Izquierdo Sr., PhD Abstract e12539: Transcriptomic mapping on Notch signaling in A luminal phenotype breast cancer. First Author: Katerin Ingrid Rojas, MD Abstract e12540: Association of blood inflammatory/immune markers with outcomes in (neo)adjuvant breast cancer: A large single institutional study. First Author: Hanis Mariyah Mohd Ishak Abstract e12542: Prediction of long-term prognosis over ten years in ER-positive HER2-negative early-stage breast cancer using 18F-FDG PET/CT before treatment. First Author: Hiroko Tsukada, MD, PhD Abstract e12544: COVID-19 outcomes in patients with a history of breast cancer: A diverse multicenter Los Angeles cohort study. First Author: Nikhita Kathuria-Prakash, MD Abstract e12545: The role of C-reactive protein (CRP) as a prognostic biomarker in patients with early breast cancer (EBC) treated with neoadjuvant chemotherapy (NACT). First Author: Hans-Christian Kolberg, MD, PhD Abstract e12546: Association of triple negative breast cancer (TNBC) with high thermogenesis with worse survival and unfavorable tumor microenvironment (TME). First Author: Shipra Gandhi, MD Abstract e12547: Impact of body mass index on the prognosis of Japanese women with operable hormone receptor-positive breast cancer: A single institutional retrospective study. First Author: Jun Masuda, MD Abstract e12548: Gasdermin D as a potential prognosis and treatment response prediction biomarker for invasive breast cancer. First Author: Xianghou Xia Abstract e12549: Gender disparity in breast cancer: A population-based study in the U.S. Department of Veterans Affairs. First Author: Zainub Ajmal, MBBS Abstract e12550: The intra-tumor heterogeneity of ER and HER2 expression in patients with ER- positive and HER2-positive breast cancer. First Author: Jie Ju, MD Abstract e12551: Ki-67 and mitotic index in triple-positive breast cancer. First Author: Maria Mikhailovna Urezkova, MD Abstract e12552: Final report of Breast Cancer Care Registry at the Kenyatta National Hospital, Nairobi. First Author: Nicholas Anthony Othieno-Abinya, MD Abstract e12553: The role of Ki67 in involved lymph nodes as a predictive biomarker for response to neoadjuvant chemotherapy in patients with early breast cancer. First Author: Cornelia Kolberg-Liedtke, MD, PhD Abstract e12554: Impact of updated 2013 human epidermal growth factor receptor-2 testing guidelines on HER2 positive invasive breast cancer diagnosis: A three year retrospective study. First Author: Hemendra Mhadgut Abstract e12555: Racial disparity in OncotypeDX score in early stage, hormone receptor positive, HER-2 negative, node negative breast cancers: A systemic review and meta-analysis. First Author: Yi Lee, MD Abstract e12556: Impact of pre-treatment derived neutrophil-lymphocyte-ratio on outcomes in patients with triple-negative breast cancer. First Author: Rakesh Kumar Sharma, MBBS, MD Abstract e12557: Predominance of RAD21 and ERBB2 amplification and progesterone receptor positivity in tumors of the right breast support breast cancer lateralization. First Author: Zachary Spigelman, MD Abstract